meta pixel code

AHC Specialty Clinic


Athens, GA Cardiometabolic Care

Redefining Weight Loss in Athens, GA: GLP-1 Therapy, Smart Tech, & Whole-Person Heart Health

Image description
Quick Answer

How does Athens Heart Center approach weight loss and diabetes? We use a whole-person approach that combines advanced GLP-1 therapies, tubeless Omnipod 5 insulin pumps paired with continuous glucose monitors (CGMs), and personalized nutrition to maximize fat loss, stabilize blood sugar, and protect vital organs. We rigorously screen for rare risks like NAION vision loss and actively prevent muscle loss (sarcopenia) through guided resistance training and protein supplementation to extend your healthy, independent years.

In This Article

The Athens Approach: Extending Your Healthspan

To our neighbors across Clarke, Oconee, Jackson, and the greater Athens metro area: we are living in an incredible era of medical advancement. For decades, the primary goal of chronic disease management was simply extending lifespan, adding years to your life. Today, our focus at the Athens Heart Center is on extending your healthspan.

We want to ensure those years are spent living vibrantly and independently, whether that means walking the trails at the State Botanical Garden, carrying your own groceries down Prince Avenue, or keeping up with your grandchildren. Achieving that independence often starts with managing weight and metabolic health as a whole person[1].


GLP-1 Therapy for Weight Loss: Balancing Benefits and NAION Vision Risks

Medications like GLP-1 receptor agonists (such as Wegovy, Ozempic, Zepbound, and Mounjaro) have revolutionized weight loss and diabetes care. For patients with diabetes, they help stabilize blood sugars. For obese individuals without diabetes, they provide the metabolic reset necessary to achieve life-changing weight loss. (If you are a senior navigating insurance costs, you can also review our guide on Medicare GLP-1 Bridge Program coverage.)

However, true whole-person care means having transparent conversations about the risks versus the rewards. In November 2026, the FDA required safety label updates on GLP-1 medications regarding a rare condition called NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy)[2].

What is NAION?

NAION is essentially a "stroke of the optic nerve" that can cause painless, permanent vision loss in one eye. The risk is highest in patients with a specific anatomical trait called a "disc at risk" combined with vascular conditions like sleep apnea or high blood pressure[3].

At the Athens Heart Center, we do not prescribe these powerful medications lightly. We comprehensively evaluate your personal risk factors (such as your optic nerve anatomy, blood pressure, cholesterol including advanced diagnostic testing like Lp(a), and sleep architecture) before you start[4]. We weigh that rare vision risk (roughly 6 cases per 100,000 patients per year) against the massive, proven benefits of GLP-1s: profound weight loss that directly reduces your risk of heart attacks, stroke, and early mortality[2].


Advanced Diabetes Management: Omnipod 5 and CGM Integration

For our patients managing Type 2 diabetes alongside their weight loss journey, we combine GLP-1 therapy with cutting-edge wearable technology to protect the body's vital organs.

Relying on multiple daily insulin injections (MDI) often leads to a roller coaster of blood sugar highs and lows. This glycemic variability acts like sandpaper on the delicate inner lining of your blood vessels. By transitioning our patients to Continuous Glucose Monitors (CGMs) paired with the Omnipod 5 tubeless patch pump, we create an Automated Insulin Delivery system, complete with hands-on Omnipod 5 training and setup right in our clinic.

Protecting the Body's Vital Organs

This 100% tubeless, waterproof patch provides continuous micro-doses of insulin guided by real-time CGM data. Clinical trials like SECURE-T2D show this technology dramatically increases your Time in Range (70-180 mg/dL)[5]. Keeping your blood sugar in this stable zone is the ultimate defense for your entire body:

The Brain

Prevents the microvascular damage that accelerates cognitive decline and dementia[6].

The Eyes

Protects the delicate retinal blood vessels from diabetic retinopathy and blindness.

The Heart & Kidneys

Reduces the oxidative stress that causes coronary artery disease and diabetic nephropathy (which leads to dialysis).

The Legs & Feet

Prevents the peripheral nerve damage (neuropathy) and poor circulation that ultimately lead to chronic leg ulcers and amputations.


Preserving Muscle and Independence: Diet and Exercise on GLP-1s

One of the biggest hidden dangers of rapid weight loss on GLP-1 medications is sarcopenia, the dangerous loss of skeletal muscle mass[7]. If you lose muscle along with fat, you risk physical frailty, accidental falls, and the loss of your ability to live safely and independently at home.

At the Athens Heart Center, an active prescription for a GLP-1 is always paired with a clinical blueprint for muscle preservation:

1

Targeted Protein Supplementation

We design individualized nutrition plans, guiding you to consume 1.0 to 1.2 grams of protein per kilogram of body weight[7]. Because GLP-1s reduce your appetite, we help you integrate high-quality protein supplements and strategically timed meals so your muscles get the fuel they need. (If your progress ever stalls along the way, explore our advanced GLP-1 plateau protocols.)

2

Progressive Resistance Training (PRT)

We don't just tell you to "exercise more." We guide you toward structured resistance training 2 to 3 times a week using weights, bands, or your own body weight to stimulate muscle protein synthesis and maintain your physical power.


Take the Next Step with Athens Heart Center

Treating the whole person means looking at how your heart, metabolism, muscles, and mind all work together. If you live in the Athens metro area and have questions about safely starting a GLP-1 for weight loss, transitioning to a tubeless Omnipod pump for your diabetes, or optimizing your long-term healthspan, we are here for you.

Contact the Athens Heart Center & Specialty Clinics today at (706) 208-9700 or visit us at 2005 Prince Avenue, Athens, GA 30606 to schedule your personalized whole-person health evaluation. Let’s build a roadmap to keep you strong, active, and thriving for decades to come.

About the Authors

SA

Dr. Subodh K. Agrawal, MD, FACC

Dr. Agrawal is a board-certified cardiologist and the founder of the Athens Heart Center. With over two decades of clinical experience in comprehensive cardiovascular care, he specializes in preventative cardiology, lipid management, and treating obesity-related heart disease. Dr. Agrawal is dedicated to helping patients utilize cutting-edge medical therapies to reduce cardiac risks and improve long-term healthspans.

AM

Dr. Aurelio D. Manto, MD

Dr. Manto is a board-certified physician specializing in internal medicine and metabolic health at the Athens Heart Center. His clinical focus centers on chronic disease prevention, weight management, and age-related metabolic shifts. Dr. Manto works closely with patients to design personalized medical, nutritional, and resistance-training regimens that ensure safe, muscle-preserving weight loss.

Clinical References Show (7) Hide
  1. American Diabetes Association (ADA). (2024). Standards of Care in Diabetes, 2024. Diabetes Care, 47(Suppl. 1).
  2. U.S. Food and Drug Administration (FDA). (2026). Drug Safety Communication: FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition (NAION).
  3. Hathaway, J. T., et al. (2024). Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmology.
  4. Tsimikas, S. (2017). A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, and Therapy. Journal of the American College of Cardiology.
  5. Pasquel, F. J., et al. (2024). Glycemic Improvement with Use of the Omnipod 5 Automated Insulin Delivery System in Adults with Type 2 Diabetes: Results of the SECURE-T2D Pivotal Trial. ADA 84th Scientific Sessions.
  6. Iadecola, C., et al. (2016). Impact of Hypertension on Cognitive Function: A Scientific Statement From the American Heart Association. Hypertension, 68(6).
  7. Cruz-Jentoft, A. J., et al. (2019). Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing.

Share Your Thoughts

No comments yet — be the first to comment!

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top
Book Appointment